Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma

The prognostic significance of the triple negative phenotype in endometrial cancer

(2010) Rajul Kothari et al.   GYNECOLOGIC ONCOLOGY

High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes

(2010) Abdulmohsen Alkushi et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

(2010) Sunil Badve et al.   MODERN PATHOLOGY

Uterine papillary serous carcinoma: Patterns of failure and survival

(2009) Wei WANG et al.   AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer

(2008) G E Konecny et al.   BRITISH JOURNAL OF CANCER

ErbB-directed immunotherapy: Antibodies in current practice and promising new agents

(2008) Elza Friedländer et al.   IMMUNOLOGY LETTERS

Outcome after combined modality treatment for uterine papillary serous carcinoma: A study by the Rare Cancer Network (RCN)

(2007) Hadassah Goldberg et al.   GYNECOLOGIC ONCOLOGY

HER-2/neuoverexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescencein situhybridization

(2007) F.E ODICINO et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER